logo
Plus   Neg
Share
Email

Genentech Announces Presentation Of New OCREVUS Data

Genentech, a member of the Roche Group (RHHBY), announced that new OCREVUS (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis or ECTRIMS from October 10-12 in Berlin, Germany.

Five-year data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO show OCREVUS efficacy is maintained on key measures of disease activity and that people treated earlier with OCREVUS had superior disability progression outcomes compared with RMS patients who switched from interferon beta-1a or PPMS patients who switched from placebo.

In the open-label extension of the Phase III OPERA I and OPERA II trials, people with RMS who had continuous OCREVUS treatment over five years had better outcomes in brain atrophy and confirmed disability progression (CDP) than patients who switched to OCREVUS after the first two years of interferon beta-1a treatment.

People with RMS who initiated OCREVUS two years earlier maintained lower whole brain, white matter and cortical grey matter tissue loss after five years of continuous treatment.

People with RMS who initiated OCREVUS treatment two years earlier achieved significant and sustained reductions in 24-week CDP compared to those who switched from interferon beta-1a (16.1 percent vs. 21.3 percent progression after Year 5, respectively, p=0.014).

In addition, people with RMS who switched to OCREVUS from interferon beta-1a after the controlled trial period had a rapid suppression of disease activity, measured with annualized relapse rate and MRI measures of T1-gadolinium enhancing (T1-Gd+) lesions and new/enlarging T2 (N/E T2) lesions.

Switching to OCREVUS reduced the annualized relapse rate from 0.2 pre-switch to 0.07 after three years of OCREVUS treatment. People also experienced near-complete suppression of T1-gadolinium enhancing (T1-Gd+) lesions from 0.49 lesions/scan on interferon beta-1a treatment to 0.004 lesions/scan after three years of OCREVUS treatment. Similarly, the number of new or enlarging T2 (N/E T2) lesions were suppressed from 2.58 to 0.038 lesions/scan.

PPMS patients who were treated with OCREVUS three to five years earlier had less disability progression in the open-label extension study of the Phase III ORATORIO trial. Disability progression was significantly reduced by 9.6 percent in people who were continuously treated with OCREVUS compared with those who switched from placebo as measured by 24-week CDP (p=0.023).

A post-hoc analysis of the ORATORIO study demonstrating OCREVUS treatment increased the proportion of patients with PPMS who achieved no evidence of progression or active disease (NEPAD), a comprehensive measure of MS, compared to placebo were published August, 29 2018 in Annals of Neurology.

OCREVUS is now approved in 68 countries across North America, South America, the Middle East, Eastern Europe, as well as in Australia, Switzerland and the European Union. Marketing applications are currently under review in more than 20 countries across the world.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

26 Articles
Editors Pick
Despite opposition from the pharmaceutical industry, President Donald Trump's administration has proposed a new rule requiring companies to include the prices for prescription drug and biological products in their television advertisements. Ride-hailing company Lyft introduced a new monthly subscription plan that offers free or discounted rides for a price of $299 every 30 days. Passengers can subscribe to the monthly plan, starting today. It will be available to everyone in the U.S. by the end of the week. With an All-Access Plan, riders can get 30 rides each month worth up to $15 each. Amazon.com Inc. will continue to work with the U.S. Department of Defense or DoD despite criticism from its employees and privacy activists, the company's Founder and Chief Executive Jeff Bezos said Monday. "If big tech companies are going to turn their back on the DoD, this country is going to be in trouble," Bezos said during the Wired25 conference in San Francisco.
Follow RTT